兆科眼科：NVK002新药上市申请获受理

Core Viewpoint - The National Medical Products Administration of China has accepted the new drug application for NVK002 (Atropine Sulfate Eye Drops 0.02%), which is designed to be administered once daily to control the progression of myopia in children [1] Group 1: Market Potential - There are approximately 700 million myopia patients in China, with 163 million being children and adolescents, indicating a significant market demand for NVK002 [1]